314 related articles for article (PubMed ID: 29990501)
1. Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation.
Zeng H; Jorapur A; Shain AH; Lang UE; Torres R; Zhang Y; McNeal AS; Botton T; Lin J; Donne M; Bastian IN; Yu R; North JP; Pincus L; Ruben BS; Joseph NM; Yeh I; Bastian BC; Judson RL
Cancer Cell; 2018 Jul; 34(1):56-68.e9. PubMed ID: 29990501
[TBL] [Abstract][Full Text] [Related]
2. BRN2 is a non-canonical melanoma tumor-suppressor.
Hamm M; Sohier P; Petit V; Raymond JH; Delmas V; Le Coz M; Gesbert F; Kenny C; Aktary Z; Pouteaux M; Rambow F; Sarasin A; Charoenchon N; Bellacosa A; Sanchez-Del-Campo L; Mosteo L; Lauss M; Meijer D; Steingrimsson E; Jönsson GB; Cornell RA; Davidson I; Goding CR; Larue L
Nat Commun; 2021 Jun; 12(1):3707. PubMed ID: 34140478
[TBL] [Abstract][Full Text] [Related]
3. Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor.
Boyle GM; Woods SL; Bonazzi VF; Stark MS; Hacker E; Aoude LG; Dutton-Regester K; Cook AL; Sturm RA; Hayward NK
Pigment Cell Melanoma Res; 2011 Jun; 24(3):525-37. PubMed ID: 21435193
[TBL] [Abstract][Full Text] [Related]
4. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.
Goel VK; Ibrahim N; Jiang G; Singhal M; Fee S; Flotte T; Westmoreland S; Haluska FS; Hinds PW; Haluska FG
Oncogene; 2009 Jun; 28(23):2289-98. PubMed ID: 19398955
[TBL] [Abstract][Full Text] [Related]
5. NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF.
Fane ME; Chhabra Y; Hollingsworth DEJ; Simmons JL; Spoerri L; Oh TG; Chauhan J; Chin T; Harris L; Harvey TJ; Muscat GEO; Goding CR; Sturm RA; Haass NK; Boyle GM; Piper M; Smith AG
EBioMedicine; 2017 Feb; 16():63-75. PubMed ID: 28119061
[TBL] [Abstract][Full Text] [Related]
6. Met amplification and tumor progression in Cdkn2a-deficient melanocytes.
Vanbrocklin MW; Robinson JP; Whitwam T; Guilbeault AR; Koeman J; Swiatek PJ; Vande Woude GF; Khoury JD; Holmen SL
Pigment Cell Melanoma Res; 2009 Aug; 22(4):454-60. PubMed ID: 19422607
[TBL] [Abstract][Full Text] [Related]
7. Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients.
Ghiorzo P; Villaggio B; Sementa AR; Hansson J; Platz A; Nicoló G; Spina B; Canepa M; Palmer JM; Hayward NK; Bianchi-Scarrà G
Hum Pathol; 2004 Jan; 35(1):25-33. PubMed ID: 14745721
[TBL] [Abstract][Full Text] [Related]
8. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma.
McNeal AS; Liu K; Nakhate V; Natale CA; Duperret EK; Capell BC; Dentchev T; Berger SL; Herlyn M; Seykora JT; Ridky TW
Cancer Discov; 2015 Oct; 5(10):1072-85. PubMed ID: 26183406
[TBL] [Abstract][Full Text] [Related]
9. Unexpected High Levels of BRN2/POU3F2 Expression in Human Dermal Melanocytic Nevi.
Chitsazan A; Lambie D; Ferguson B; Handoko HY; Gabrielli B; Walker GJ; Boyle GM
J Invest Dermatol; 2020 Jun; 140(6):1299-1302.e4. PubMed ID: 31881210
[No Abstract] [Full Text] [Related]
10. BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma.
Herbert K; Binet R; Lambert JP; Louphrasitthiphol P; Kalkavan H; Sesma-Sanz L; Robles-Espinoza CD; Sarkar S; Suer E; Andrews S; Chauhan J; Roberts ND; Middleton MR; Gingras AC; Masson JY; Larue L; Falletta P; Goding CR
Genes Dev; 2019 Mar; 33(5-6):310-332. PubMed ID: 30804224
[TBL] [Abstract][Full Text] [Related]
11. BRN2 is a transcriptional repressor of CDH13 (T-cadherin) in melanoma cells.
Ellmann L; Joshi MB; Resink TJ; Bosserhoff AK; Kuphal S
Lab Invest; 2012 Dec; 92(12):1788-800. PubMed ID: 23069940
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of BRN2 modulates its interaction with the Pax3 promoter to control melanocyte migration and proliferation.
Berlin I; Denat L; Steunou AL; Puig I; Champeval D; Colombo S; Roberts K; Bonvin E; Bourgeois Y; Davidson I; Delmas V; Nieto L; Goding CR; Larue L
Mol Cell Biol; 2012 Apr; 32(7):1237-47. PubMed ID: 22290434
[TBL] [Abstract][Full Text] [Related]
13. POU transcription factors in melanocytes and melanoma.
Besch R; Berking C
Eur J Cell Biol; 2014; 93(1-2):55-60. PubMed ID: 24315688
[TBL] [Abstract][Full Text] [Related]
14. BRN2, a POUerful driver of melanoma phenotype switching and metastasis.
Fane ME; Chhabra Y; Smith AG; Sturm RA
Pigment Cell Melanoma Res; 2019 Jan; 32(1):9-24. PubMed ID: 29781575
[TBL] [Abstract][Full Text] [Related]
15. A phosphatidylinositol 3-kinase-Pax3 axis regulates Brn-2 expression in melanoma.
Bonvin E; Falletta P; Shaw H; Delmas V; Goding CR
Mol Cell Biol; 2012 Nov; 32(22):4674-83. PubMed ID: 22988297
[TBL] [Abstract][Full Text] [Related]
16. Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination.
Pinner S; Jordan P; Sharrock K; Bazley L; Collinson L; Marais R; Bonvin E; Goding C; Sahai E
Cancer Res; 2009 Oct; 69(20):7969-77. PubMed ID: 19826052
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT.
Daniotti M; Ferrari A; Frigerio S; Casieri P; Miselli F; Zucca E; Collini P; Della Torre G; Manoukian S; Peissel B; Bono A; Santinami M; Parmiani G; Rivoltini L; Pilotti S; Rodolfo M
J Invest Dermatol; 2009 Jul; 129(7):1759-68. PubMed ID: 19158841
[TBL] [Abstract][Full Text] [Related]
18. Effects of CDKN2A (p16INK4A/p14ARF) Over-Expression on Proliferation and Migration of Human Melanoma A375 Cells.
Bai M; Yu NZ; Long F; Feng C; Wang XJ
Cell Physiol Biochem; 2016; 40(6):1367-1376. PubMed ID: 27997910
[TBL] [Abstract][Full Text] [Related]
19. Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16(INK4) and p27(KIP1) to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes.
Haddad MM; Xu W; Schwahn DJ; Liao F; Medrano EE
Exp Cell Res; 1999 Dec; 253(2):561-72. PubMed ID: 10585280
[TBL] [Abstract][Full Text] [Related]
20. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.
Chudnovsky Y; Adams AE; Robbins PB; Lin Q; Khavari PA
Nat Genet; 2005 Jul; 37(7):745-9. PubMed ID: 15951821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
